Please assess the completion status of the following clinical trial:

Trial Title: Shift to Everolimus (RAD) Kidney Sparing Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heart Transplant with 1 to 4 years of follow-up~* GFR between 20 and 60 ml/min (calculated with Colkoroft-Gault formula)~Exclusion Criteria:~* Acute rejection in the previous 6 months~* Contraindications to statin therapy~* Ongoing infection~* Ongoing heart failure~* Myocardial infarction or myocardial revascularization after transplant~* Malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mycophenolate (Type: ACTIVE_COMPARATOR): Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
- Everolimus (Type: ACTIVE_COMPARATOR): Everolimus with cyclosporine trough levels between 40 and 90 ng/ml

Based on this trial design, predict the completion outcome and termination type (if applicable).